Parexel appoints Jim Anthony as CCO and President, Parexel Biotech
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The company is bringing precision therapies for gynaecological cancers
This project shall be implemented through incorporation of a new joint venture company in Zambia
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The company has improved access to quality healthcare for seniors across both urban and rural areas
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The facility will be positioned as a Centre of Excellence for tertiary care services
Subscribe To Our Newsletter & Stay Updated